AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

DIMERIX LTD

0.545

-0.005-0.91%

Volume:1.13M

Turnover:620.06K

Market Cap:327.08M

PE:-12.33

High:0.560

Open:0.550

Low:0.540

Close:0.550

Loading ...

Overview Company News Filings

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Dimerix Ltd - Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for Dmx-200 in United States

THOMSON REUTERS

Dimerix Ltd - Dimerix to Receive US$30 Mln Upfront Payment

THOMSON REUTERS

BRIEF-Dimerix Seeks Trading Halt

Dimerix - Seeks Trading Halt Pending Announcement on Licensing Agreement

THOMSON REUTERS

Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal

MT Newswires Live

BRIEF-Dimerix Receives Initial Upfront Payment From FUSO

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

The Market Herald

Dimerix Ltd - Dimerix Receives Initial Upfront Payment From Fuso

THOMSON REUTERS

BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 Mln

Dimerix Ltd - Loss for Half-Year Attributable a$12.9 Mln

THOMSON REUTERS

Lowering Dimerix's Phase 3 Trial Hurdles to Boost Kidney Failure Treatment Drug Appeal, Euroz Hartleys Says.

MT Newswires Live

Emirates Takes Flight as First Autism-Certified Airline

ASX Market Close: Financials lead index higher | January 16, 2025

The Market Herald

Dimerix Recruits First Paediatric Patient for Kidney Disease Drug Trial

MT Newswires Live

Sparc fires up following three-way hydrogen tie-in

The Sydney Morning Herald

Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DXB.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.545,"timestamp":1752819120000,"preClose":0.55,"halted":0,"volume":1130521,"delay":0,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600142896,"eps":-0.044195,"marketStatus":"Market Closed","change":-0.005,"latestTime":"07-18 16:12:00 AEST","open":0.55,"high":0.56,"low":0.54,"amount":620062,"amplitude":0.036364,"askPrice":0.545,"askSize":49999,"bidPrice":0.54,"bidSize":22049,"shortable":3,"etf":0,"ttmEps":-0.044195,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1753056000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.55,"openAndCloseTimeList":[[1752796800000,1752818400000]],"volumeRatio":0.9787631814232637,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-79.26%","roe":"-524.68%","lyrEps":-0.0377,"volumeRatio":0.9787631814232637,"shares":600142896,"dividePrice":0,"high":0.56,"amplitude":0.036364,"preClose":0.55,"low":0.54,"week52Low":0.3,"pbRate":"45.63","psRate":"443.27","week52High":0.785,"institutionHeld":0,"latestPrice":0.545,"committee":-0.387936,"eps":-0.044195,"divideRate":0,"volume":1130521,"delay":0,"ttmEps":-0.044195,"open":0.55,"prevYearClose":0.34,"prevWeekClose":0.53,"prevMonthClose":0.575,"prevQuarterClose":0.575,"fiveDayClose":0.53,"twentyDayClose":0.565,"sixtyDayClose":0.425},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532601534","title":"Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532601534","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532601534?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:12","pubTimestamp":1746054720,"startTime":"0","endTime":"0","summary":"Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis . DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies. Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval. Dimerix to receive US$30 million  upfront payment, up to US$560 million  for success-based milestone payments, in addition to tiered royalties on DMX-200 net U.S. sales. “We are delighted to partner with Amicus in the United States. The Amicus team has a remarkable history of successfully delivering rare disease medicines to those in need. Their expertise and resources will be crucial to help achieve our mutual objective of commercializing this innovative treatment,” said Dr. Nina Webster, CEO and Managing Director of Dimerix. “I’m grateful to the dedicated Dimerix team, trial participants, and investigators for their contin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dimerix-amicus-therapeutics-announce-exclusive-231200447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARB","LU2065171402.SGD","UBCP","DMX","FOLD","DXBO.AU","DXB.AU","LU2065169927.USD","LU2065171311.SGD","BK4139","FSGS","BK4211","LU2065170008.USD"],"gpt_icon":0},{"id":"2532130930","title":"Dimerix Ltd -  Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for Dmx-200 in United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532130930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532130930?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:10","pubTimestamp":1746054655,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2532015821","title":"Dimerix Ltd -  Dimerix to Receive US$30 Mln Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2532015821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532015821?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:10","pubTimestamp":1746054655,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","DXB.AU","BK7508"],"gpt_icon":0},{"id":"2531319216","title":"BRIEF-Dimerix Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2531319216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531319216?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:44","pubTimestamp":1745891050,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Seeks Trading HaltApril 29 (Reuters) - Dimerix Ltd DXB.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON LICENSING AGREEMENTFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","BK7067","BK7501","BK7508"],"gpt_icon":0},{"id":"2531298476","title":"Dimerix - Seeks Trading Halt Pending Announcement on Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2531298476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531298476?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:32","pubTimestamp":1745879522,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2516136766","title":"Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516136766","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516136766?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:32","pubTimestamp":1741059169,"startTime":"0","endTime":"0","summary":"Dimerix  received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7501","BK7067","XAO.AU","BK7508","DXB.AU","XJO.AU","DMX"],"gpt_icon":0},{"id":"2516269987","title":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516269987?lang=en_us&edition=fundamental","pubTime":"2025-03-04 09:23","pubTimestamp":1741051414,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSOMarch 4  - Dimerix Ltd DXB.AX:RECEIVED UPFRONT PAYMENT OF 300 MILLION FROM FUSO PHARMACEUTICAL INDUSTRIESDIMERIX RECEIVES INITIAL UPFRONT PAYMENT FROM FUSOANTICIPATES A FURTHER 400 MILLION FROM FUSOFurther company coverage: DXB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2516692168","title":"Dimerix posts modest gain as first Japanese payment for DMX-200 lands","url":"https://stock-news.laohu8.com/highlight/detail?id=2516692168","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516692168?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:46","pubTimestamp":1741045560,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January.Under that deal, FUSO and Dimerix teamed up to develop and commercialise Dimerix’s drug ‘DMX-200’ in Japan, which treats Focal Segmental Glomerulosclerosis , a scar tissue disease affecting kidneys.The $3.2M upfront payment is the first of multiple Dimerix expects, with up to $30M in payments possible under the FUSO deal. Another $4.1M is expected in the next six to 12 weeks as the first clinical trial in Japan begins.That timeframe is based on the certainty FUSO is already identifying trial sites ahead of the ‘ACTION3’ trial. Notably, FUSO is also responsible for all trial costs.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-posts-modest-gain-as-first-japanese-payment-for-dmx-200-lands-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","BK7501","FSGS","DMX","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2516666705","title":"Dimerix Ltd - Dimerix Receives Initial Upfront Payment From Fuso","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516666705?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:33","pubTimestamp":1741037617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0YV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2514803966","title":"BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514803966?lang=en_us&edition=fundamental","pubTime":"2025-02-25 12:36","pubTimestamp":1740458171,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 MlnFeb 25 (Reuters) - Dimerix Ltd DXB.AX:LOSS FOR HALF-YEAR ATTRIBUTABLE A$12.9 MILLIONFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF23H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","DXB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2514704820","title":"Dimerix Ltd -  Loss for Half-Year Attributable a$12.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514704820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514704820?lang=en_us&edition=fundamental","pubTime":"2025-02-25 06:08","pubTimestamp":1740434926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF23H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2510721814","title":"Lowering Dimerix's Phase 3 Trial Hurdles to Boost Kidney Failure Treatment Drug Appeal, Euroz Hartleys Says.","url":"https://stock-news.laohu8.com/highlight/detail?id=2510721814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510721814?lang=en_us&edition=fundamental","pubTime":"2025-02-11 07:40","pubTimestamp":1739230827,"startTime":"0","endTime":"0","summary":"Lowering the approval hurdles in Dimerix's (ASX:DXB) Phase 3 trial is expected to boost the success, value, and appeal of the company's kidney failure therapy, DMX-200, to potential US partners, accor","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7508","BK7067","BK7501"],"gpt_icon":0},{"id":"2505974112","title":"Emirates Takes Flight as First Autism-Certified Airline","url":"https://stock-news.laohu8.com/highlight/detail?id=2505974112","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505974112?lang=en_us&edition=fundamental","pubTime":"2025-01-21 13:52","pubTimestamp":1737438735,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -Dubai-based airline Emirates announced that they have become the world's first Autism Certified Airline  carrier. This achievement is the result of a collaborative effort with the International Board of Credentialing and Continuing Education Standards  to establish more inclusive travel standards and services for passengers with autism and sensory sensitivities.As reported on the official Emirates website, this initiative is designed to transform air travel into a more accessible and friendly experience for individuals who require additional support during flights.","market":"sh","thumbnail":"https://statik.tempo.co/data/2019/01/13/id_811238/811238_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2019/01/13/id_811238/811238_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1966397/emirates-takes-flight-as-first-autism-certified-airline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK7067","BK4129","LU0274383776.USD","DXB.AU","ACA","DXB","BK7501","IE0034390439.USD","BK7508","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2503322209","title":"ASX Market Close: Financials lead index higher | January 16, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503322209","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503322209?lang=en_us&edition=fundamental","pubTime":"2025-01-16 14:04","pubTimestamp":1737007440,"startTime":"0","endTime":"0","summary":"The ASX200 closed up 1.38% at 8,327 points.Unemployment ticked up to 4%, in line with consensus expectations. The strong jobs data has increased the threshold on what the RBA will need to see in the December quarter inflation numbers for any chance of a February rate cut.Moody’s Harry Murphy Hughes says underlying inflation at or under 3.2% year on year  would probably do the trick. And anything above that would likely see the board wait until May. Moody’s expect underlying inflation to come in at 3.3%.The Financials sector was the best performer, up 2.5%, followed by Real Estate, up 2.25%, and IT, up 1.8%.Helios Energyclosed up 14.3% after an independent contingent resource report confirmed hydrocarbon resources at the Presidio Project in West Texas.BHP closed up 0.5% after finalising a major acquisition with Lundin Mining, securing the full ownership of Filo Corp. and establishing a joint venture for the Filo del Sol and Josemaria copper projects in Argentina and Chile.Vulcan Energy ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-financials-lead-index-higher-january-16-2025-2025-01-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LU2089283258.USD","LU0314104364.USD","LU0795875086.SGD","BK7130","BK4127","LU0225283273.USD","LU2028103732.USD","LU2089284900.SGD","LHM.AU","LU0795875169.SGD","LU1548497426.USD","LU0971096721.USD","LU1668664300.SGD","LU1732799900.SGD","LU2347655156.SGD","LU1720051108.HKD","VUL.AU","BK7508","BK7067","HE8.AU","BK7016","360.AU","LU2023251221.USD","ORG.AU","BK4585","LU1074936037.SGD","LU1989772840.SGD","LU1732800096.USD","LU0267386448.USD","LU0106831901.USD","BK7511","LU0006306889.USD","LU1989772923.USD","BK7504","LU2357305700.SGD","LU1162221912.USD","BK7145","LU2271345857.HKD","BK7006","LU0098860793.USD","BK4581","BK4516","DXB.AU","BHP.AU","IE00BKVL7J92.USD","LU2111349929.HKD","BK7142","LU0320765646.SGD","LU0158827948.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2503989334","title":"Dimerix Recruits First Paediatric Patient for Kidney Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503989334","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503989334?lang=en_us&edition=fundamental","pubTime":"2025-01-16 10:04","pubTimestamp":1736993040,"startTime":"0","endTime":"0","summary":"Dimerix  recruited the first paediatric patient for the phase-three clinical trial for DMX-200, the company's drug candidate for kidney disease, according to a Thursday filing with the Australian bourse.The biopharmaceutical company is assessing the efficacy and safety of DMX-200 in patients with focal and segmental glomerulosclerosis , a rare disease that attacks the kidney's filtering units, per the filing.A total of 19 specialist paediatric clinical sites across Argentina, Mexico, the UK, and the US will recruit patients into the clinical trial.The biopharmaceutical company expects the blinded interim analysis in August.Dimerix's shares were up 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","FSGS","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2502839668","title":"Sparc fires up following three-way hydrogen tie-in","url":"https://stock-news.laohu8.com/highlight/detail?id=2502839668","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502839668?lang=en_us&edition=fundamental","pubTime":"2025-01-10 14:09","pubTimestamp":1736489340,"startTime":"0","endTime":"0","summary":"This week the market again encountered a diverse mix of high-flying winners, with those finding favour on the market comprising a new-age hydrogen tech developer, an immune-related disorder biopharma firm, a mining company growing its scandium critical mineral resource and a drug developer joining forces with a Japanese pharmaceutical firm to fight kidney disease.This week’s Bulls N’ Bears ASX Runner of the Week is…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/sparc-fires-up-following-three-way-hydrogen-tie-in-20250110-p5l3fv.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["BK7067","SPN.AU","BK7501","BK7036","BK7096","BK7508","BK7504","DXB.AU","RGT.AU","AUZ.AU","BK7095"],"gpt_icon":0},{"id":"2502270057","title":"Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2502270057","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502270057?lang=en_us&edition=fundamental","pubTime":"2025-01-09 13:41","pubTimestamp":1736401282,"startTime":"0","endTime":"0","summary":"Dimerix's  exclusive licensing agreement in Japan for its kidney disease drug candidate is a \"positive surprise,\" presenting additional value for the firm in the region, according to a Thursday note from Euroz Hartleys.Dimerix disclosed Tuesday that it entered into an exclusive development and license agreement worth a total of AU$107 million with Fuso Pharmaceutical Industries to develop and commercialize its drug candidate, DMX-200, to treat focal segmental glomerulosclerosis  in Japan.The Fuso licensing deal, Dimerix's third such deal, validates the ability of the firm's management to license across multiple territories, including in key markets like the US and Mainland China.Collectively, these licensing deals provide the company up to AU$458 million in upfront and potential milestone payments, as well as royalties on net sales.Importantly, Fuso, as a leading firm in the dialysis and renal/urology field, is well-positioned as an ideal partner for Dimerix in the region, the note sai","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FSGS","DXB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[]}}